Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Basic Medicine
  4. Vol 1, Issue 2, 2023

Clinical Analysis of Multidrug Resistance-Related Protein Expression in Gastric Cancer Cells

Download as PDF

DOI: 10.23977/medbm.2023.010211 | Downloads: 8 | Views: 336

Author(s)

Xiaomeng Chen 1, Xinyu Zheng 1, Xiaoxiao Zhou 1, Wenzhen Wang 1, Qian Liu 1, Xingzhou Xia 1

Affiliation(s)

1 The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China

Corresponding Author

Xingzhou Xia

ABSTRACT

This study investigated the expression of multidrug resistance-related proteins in gastric cancer cells using archival paraffin blocks from 50 surgical specimens collected between 2021 and 2022. The analysis included P-glycoprotein (P-gp), glutathione S-transferase pi (GST-π), and B-cell lymphoma-extra-large (Bcl-xL). The positive expression rates and high expression levels of P-gp, GST-π, and Bcl-xL were significantly higher in gastric cancer tissues compared to normal gastric mucosa tissues. The expression of these multidrug resistance proteins did not show significant associations with clinical characteristics but revealed a positive correlation between Bcl-xL expression and tumor differentiation degree. These findings provide insights into the expression patterns of multidrug resistance-related proteins in gastric cancer tissues, contributing to the understanding of their relationship with multidrug resistance in gastric cancer.

KEYWORDS

Gastric cancer cells; multidrug resistance-related proteins; clinical analysis

CITE THIS PAPER

Xiaomeng Chen, Xinyu Zheng, Xiaoxiao Zhou, Wenzhen Wang, Qian Liu, Xingzhou Xia, Clinical Analysis of Multidrug Resistance-Related Protein Expression in Gastric Cancer Cells. MEDS Basic Medicine (2023) Vol. 1: 65-72. DOI: http://dx.doi.org/10.23977/medbm.2023.010211.

REFERENCES

[1] Smyth, E.C., et al., Gastric cancer. Lancet, 2020. 396(10251): p. 635-648.
[2] Tan, Z., Recent Advances in the Surgical Treatment of Advanced Gastric Cancer: A Review. Med Sci Monit, 2019. 25: p. 3537-3541.
[3] Wang, Q., et al., APAF1-Binding Long Noncoding RNA Promotes Tumor Growth and Multidrug Resistance in Gastric Cancer by Blocking Apoptosome Assembly. Adv Sci (Weinh), 2022. 9(28): p. e2201889.
[4] Fernandes, E.S.E., et al., C-Phycocyanin: Cellular targets, mechanisms of action and multi drug resistance in cancer. Pharmacol Rep, 2018. 70(1): p. 75-80.
[5] Wu, Y., et al., Impact of MiRNAs and LncRNAs on Multidrug Resistance of Gastric Cancer. Comb Chem High Throughput Screen, 2022. 25(13): p. 2127-2140.
[6] Czupiel, P.P., V. Delplace, and M.S. Shoichet, Cationic block amphiphiles show anti-mitochondrial activity in multi-drug resistant breast cancer cells. J Control Release, 2019. 305: p. 210-219.
[7] Wang, M., et al., Abnormal saccharides affecting cancer multi-drug resistance (MDR) and the reversal strategies. Eur J Med Chem, 2021. 220: p. 113487.
[8] Bonitto, E.P., B.T. McKeown, and K.B. Goralski, Jadomycins: A potential chemotherapy for multi-drug resistant metastatic breast cancer. Pharmacol Res Perspect, 2021. 9(6): p. e00886.
[9] Wang, Y., et al., The role of non-coding RNAs in ABC transporters regulation and their clinical implications of multidrug resistance in cancer. Expert Opin Drug Metab Toxicol, 2021. 17(3): p. 291-306.
[10] He, J., et al., LncRNA as a multifunctional regulator in cancer multi-drug resistance. Mol Biol Rep, 2021. 48(8): p. 1-15.
[11] Xu, F., et al., Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours. Cell Biosci, 2020. 10(1): p. 54.
[12] Tewari, D., et al., Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy. Semin Cancer Biol, 2022. 80: p. 1-17.
[13] Wu, D., S. Tian, and W. Zhu, Modulating multidrug resistance to drug-based antitumor therapies through NF-kappaB signaling pathway: mechanisms and perspectives. Expert Opin Ther Targets, 2023. 27(6): p. 503-515.
[14] Hsu, H.H., et al., Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis. J Cell Physiol, 2018. 233(7): p. 5458-5467.
[15] Wang, Z., et al., Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-kappaB-Nrf2 signaling in colorectal cancer cell. Phytomedicine, 2021. 82: p. 153414.
[16] Zhang, D. and D. Fan, Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert Rev Anticancer Ther, 2007. 7(10): p. 1369-1378.
[17] Zeng, X., et al., The Roles of microRNAs in Multidrug-Resistance Mechanisms in Gastric Cancer. Curr Mol Med, 2020. 20(9): p. 667-674.
[18] Duan, C., et al., Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges. Biomed Pharmacother, 2023. 162: p. 114643.
[19] Zhang, D. and D. Fan, New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol, 2010. 6(4): p. 527-537.
[20] Mowla, M. and A. Hashemi, Functional roles of exosomal miRNAs in multi-drug resistance in cancer chemotherapeutics. Exp Mol Pathol, 2021. 118: p. 104592.
[21] Yang Jian and Zhou Yejiang, Study on multidrug resistance protein levels in AFP positive gastric cancer. Journal of Gastroenterology and Hepatology, 2017.26 (12): p. 1365-1369.
[22] Tan, W., et al., Deciphering the metabolic role of AMPK in cancer multi-drug resistance. Semin Cancer Biol, 2019. 56: p. 56-71.
[23] Kaur, G., et al., Drug-metabolizing enzymes: role in drug resistance in cancer. Clin Transl Oncol, 2020. 22(10): p. 1667-1680.
[24] Estrada, D.F., et al., Crystal Structures of Drug-Metabolizing CYPs. Methods Mol Biol, 2021. 2342: p. 171-192.
[25] de Man, F.M., et al., Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. Clin Pharmacokinet, 2018. 57(10): p. 1229-1254.
[26] Knights, K.M., A. Rowland, and J.O. Miners, Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT). Br J Clin Pharmacol, 2013. 76(4): p. 587-602.
[27] Zhang Li, et al., Bcl-2, and the significance of its expression in paclitaxel-resistant gastric adenocarcinoma cells. Journal of Anhui Medical University, 2014.49 (8): p. 1048-1052.
[28] Geng, M., et al., The association between chemosensitivity and Pgp, GST-pi and Topo II expression in gastric cancer. Diagn Pathol, 2013. 8: p. 198.
[29] Alam, M. and R. Mishra, Bcl-xL expression and regulation in the progression, recurrence, and cisplatin resistance of oral cancer. Life Sci, 2021. 280: p. 119705.
[30] Sciskalska, M. and H. Milnerowicz, The role of GSTpi isoform in the cells signalling and anticancer therapy. Eur Rev Med Pharmacol Sci, 2020. 24(16): p. 8537-8550.
[31] Bui, A.T.N., et al., Artificial intelligence-based identification of octenidine as a Bcl-xL inhibitor. Biochem Biophys Res Commun, 2022. 588: p. 97-103.
[32] Shishido, Y., et al., A Covalent Inhibitor for Glutathione S-Transferase Pi (GSTP(1-1) ) in Human Cells. Chembiochem, 2019. 20(7): p. 900-905.
[33] Mollazadeh, S., et al., Structural and functional aspects of P-glycoprotein and its inhibitors. Life Sci, 2018. 214: p. 118-123.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 431
Visits: 13510

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.